Morning Market Losers

shares dipped 68.73% to $1.97 on failed Pracinostat and azacitidine Phase II study.

shares declined 8.40% to $3.71. Global-Tech Advanced Innovations posted a Q3 net loss of $1.8 million, or $0.59 per share, on sales of $16.2 million.

shares fell 6.75% to $107.88 after the company cut its 2015 sales growth forecast.

shares dropped 6.41% to $122.60 after the company reported data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor.

shares slipped 1.97% to $100.27 following a Bloomberg report of death of hepatitis patient on heart drug

shares declined 1.58% to $46.14. Deutsche Bank downgraded Carnival from Buy to Hold.

dropped 1.53% to $468.70. The company reported that effective today, Biogen Idec will be known simply as Biogen. Stifel Nicolaus downgraded Biogen from Buy to Hold.